450 related articles for article (PubMed ID: 16136007)
1. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M
Neuro Endocrinol Lett; 2005 Aug; 26(4):367-72. PubMed ID: 16136007
[TBL] [Abstract][Full Text] [Related]
2. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
3. Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M; Boczek-Leszczyk E
J Physiol Pharmacol; 2008 Sep; 59(3):553-62. PubMed ID: 18953097
[TBL] [Abstract][Full Text] [Related]
4. Role of tachykinin receptors and melatonin in oxitocin secretion from isolated rat hypothalmo-neurohypophysial system.
Juszczak M; Furykiewicz-Nykiś K; Stempniak B
J Physiol Pharmacol; 2004 Dec; 55(4):739-49. PubMed ID: 15613740
[TBL] [Abstract][Full Text] [Related]
5. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
6. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
7. Role for NK(1) and NK(2) receptors in the motor activity in mouse colon.
Mulè F; Amato A; Serio R
Eur J Pharmacol; 2007 Sep; 570(1-3):196-202. PubMed ID: 17597603
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
9. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
11. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
[TBL] [Abstract][Full Text] [Related]
12. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological examination of the neurokinin-1 receptor mediating relaxation of human intralobar pulmonary artery.
Pedersen KE; Buckner CK; Meeker SN; Undem BJ
J Pharmacol Exp Ther; 2000 Jan; 292(1):319-25. PubMed ID: 10604965
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory and motor responses by tachykinins in the guinea-pig oesophageal sphincter.
Conte B; Parlani M; Lopez G; Cirillo R; Maggi CA; Manzini S
J Auton Pharmacol; 1998 Oct; 18(5):313-7. PubMed ID: 9831232
[TBL] [Abstract][Full Text] [Related]
15. Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers or healthy volunteers.
Brunelleschi S; Nicali R; Lavagno L; Viano I; Pozzi E; Gagliardi L; Ghio P; Albera C
Neuropeptides; 2000 Feb; 34(1):45-50. PubMed ID: 10688968
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective tachykinin-receptor antagonists on tachykinin-induced airway mucus secretion in the rat.
Wagner U; Fehmann H; Bredenbröker D; Klüber D; Lange A; Wichert P
Neuropeptides; 1999 Feb; 33(1):55-61. PubMed ID: 10657472
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin A and senktide attenuate scopolamine-induced impairment of spontaneous alternation performance in mice.
Ukai M; Shinkai N; Kameyama T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Jun; 16(3):97-101. PubMed ID: 8905797
[TBL] [Abstract][Full Text] [Related]
18. Presence of NK1 receptors on a mucosal-like mast cell line, RBL-2H3 cells.
Cooke HJ; Fox P; Alferes L; Fox CC; Wolfe SA
Can J Physiol Pharmacol; 1998 Feb; 76(2):188-93. PubMed ID: 9635159
[TBL] [Abstract][Full Text] [Related]
19. In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376.
Maggi CA; Giuliani S; Ballati L; Lecci A; Manzini S; Patacchini R; Renzetti AR; Rovero P; Quartara L; Giachetti A
J Pharmacol Exp Ther; 1991 Jun; 257(3):1172-8. PubMed ID: 1710662
[TBL] [Abstract][Full Text] [Related]
20. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
Nordquist RE; Durkin S; Jacquet A; Spooren W
Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
